Organization · Venture Capital
NelGaard Capital
NelGaard Capital is a pre-seed and seed-stage venture architect firm based in the United States, focusing on synthetic biology and AI-driven technologies. They aim to address modern infrastructure constraints through innovative investment strategies and operational leadership.
Overview
What NelGaard Capital does
What NelGaard Capital is
NelGaard Capital is a pre-seed and seed-stage venture architect firm based in the United States, focusing on synthetic biology and AI-driven technologies. They aim to address modern infrastructure constraints through innovative investment strategies and operational leadership.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2024
- Approximate age
- About 2 years
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find NelGaard Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
NelGaard Capital as a funder
Investment thesis
NelGaard Capital focuses on architecting ventures at the intersection of synthetic biology and AI-driven technologies, aiming to collapse traditional development cycles through innovative approaches and operational leadership.
Focus narrative
NelGaard Capital specializes in investing in synthetic biology and AI-driven technologies. Their investment strategy includes providing seed capital, intellectual property strategy, and operational leadership to help founders develop their ventures. The firm is particularly focused on the intersection of breakthrough science and institutional-grade ventures, leveraging computational modeling and programmable biology to accelerate development.
Value beyond capital
NelGaard Capital adds value to its portfolio companies through operational leadership, strategic partnerships, and intellectual property strategy. The firm aims to provide a comprehensive support system that helps founders navigate the complexities of building high-potential ventures in the life sciences and TechBio sectors.
Focus and fit
- Stages
- Pre-seed · Seed
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 4
Portfolio context
Mimulus Corp: Developing Molecular Archive Technology™ for carbon-neutral archival storage. Cellari Therapeutics: Innovating mRNA-based neuromodulation for precision medicine in neuromuscular conditions. Racer Biosciences: Enhancing synthetic biology workflows with F1-X™ technology. DIENEI Co: Transforming DNA into a medium for expression and memory in entertainment.
Common questions
What to know about NelGaard Capital
Upseed classifies NelGaard Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.